The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction

The high activity of Histone deacetylases (HDACs) in hepatocellular carcinoma (HCC) usually positively correlates with poor prognosis of patients. Accordingly histone deacetylases inhibitors (HDACis) are considered to be potential agents treating patients with HCC. In our study, we evaluated effect...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Bin, Dai, Longfei, Zhang, Xiaoqian, Chen, Diyu, Wu, Jingbang, Feng, Xiaode, Zhang, Yanpeng, Xie, Haiyang, Zhou, Lin, Wu, Jian, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231215/
https://www.ncbi.nlm.nih.gov/pubmed/30443188
http://dx.doi.org/10.7150/ijbs.27661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231215/
https://www.ncbi.nlm.nih.gov/pubmed/30443188
http://dx.doi.org/10.7150/ijbs.27661

Ejemplares similares